TORONTO, Nov. 5 /PRNewswire/ - Trillium Therapeutics Inc., a privately held biopharmaceutical company, announced today that industry veterans Dr. Michael Berendt and Dr. John Dietrich have joined its Board as independent directors. Trillium Chairman Dr. Michael Moore commented: "It is a great pleasure to welcome these two experienced biotech executives to the Board where they will enhance our capabilities in strategic planning and product development. Their appointments are commensurate with completion of an internal financing round of $12 million and the entry into clinical development of Trillium's lead product, TTI-1612."
About Dr. Michael Berendt: Dr. Berendt is the President and CEO of Aegera Therapeutics. Prior to joining Aegera, he served as managing director of Research Corporation Technologies (RCT), a US-based technology investment and management company, and AEA Investors Inc., where focusing on growth equity investments in life sciences companies. Previously Dr. Berendt was Senior Vice President of Research for the Pharmaceutical Division of Bayer Corporation. He is currently a director of Waters Corporation and has served on the board of directors of numerous other life sciences companies. Dr. Berendt received a doctoral degree in medical microbiology and immunology from Hahnemann University.
About Dr. John Dietrich: Dr. Dietrich joined Ventrus Biosciences in
April 2007, where he currently serves as Vice President, Clinical
Operations. From 2000 to 2007, Dr. Dietrich was Vice President of Research
and Development at VIVUS, Inc, prior to which he was Vice President of
Research and Development at Cellegy Pharmaceuticals. Dr. Dietrich served as
Senior Vice President of Research and Development at Allelix
Biopharmaceuticals between 1991 and 1999. In this position, he was
responsible for all aspects of drug discovery and development. Before
joining Allelix, he held management positions at Chemex and Revlon Health
Care. Dr. Dietrich recei
|SOURCE Trillium Therapeutics Inc.|
Copyright©2008 PR Newswire.
All rights reserved